Polarix

Polarix.io is an AI-enabled, cloud-based platform designed for Medical Affairs professionals and scientific communications teams in pharmaceutical and biotech organizations. It provides tools to create, collaborate on, and distribute scientific content, while supporting strategic alignment between Medical Affairs and Commercial teams through centralized content management and cross-functional collaboration. The platform was developed by 9 Labs Inc. and is founded on decades of experience in medical communications, with the goal of moving scientific communication platforms (SCPs) away from static slide decks and documents into a dynamic, digital environment.

Polarix.io serves organizations that need to manage evidence-based scientific narratives consistently across global teams, ensuring compliance and enabling wider use of scientific content throughout the organization. The platform has been adopted by pharmaceutical companies and has received industry recognition, including a Gold Award for Digital Innovation at the PM Society Awards, with additional accolades in 2023.

Core Platform Capabilities

• Single Source of Truth: Scientific narratives, data, and references are centralized in one secure hub using structured templates, providing one consistent set of approved statements and evidence across the organization.
• Collaboration Tools: Real-time commenting, chat, and video conferencing support global teams working across different functions and geographies, reducing silos between Medical Affairs and Commercial teams.
• Compliance and MLR Review: A dedicated interface supports Medical, Legal, and Regulatory (MLR) review workflows, with reference-backed content and approval management to simplify the review process.
• AI-Powered Content Assistance: The platform uses advanced life-science language models to accelerate content creation and research, assisting teams in generating scientific content more efficiently.
• Analytics and Engagement Metrics: Built-in analytics track how scientific content is used and engaged with, providing actionable insights to inform content strategy.
• System Integrations: Polarix.io connects with existing technology stacks, including CRM systems, document management platforms, and MLR systems.
• Version Control and Audit Trails: Enterprise-grade version control and audit trail functionality supports governance and accountability across content workflows.

Security and Compliance Certifications

• ISO 27001: Certification covering information security management.
• SOC 2 Type 2: Compliance with Trust Services Criteria, demonstrating ongoing operational security controls.
• GDPR: Data protection compliance for handling sensitive scientific and personal data.

Deployment and Background

• Polarix.io is a cloud-based platform, purpose-built for pharmaceutical and biotech organizations.
• It is developed and maintained by 9 Labs Inc., which holds the relevant security certifications underpinning the platform.
• The platform was created in response to the limitations of traditional SCP formats, such as static slide decks and documents that were frequently underutilized.
• Polarix.io is positioned as a continuously evolving product, with ongoing integration of user feedback and feature development covering areas such as AI enhancements and workflow integrations.

Company Values and Vision

• Innovation: The company continuously evolves the platform based on user feedback and the changing needs of Medical Affairs and scientific communications teams.
• Collaboration: Breaking down organizational silos and enabling seamless teamwork across global Medical Affairs teams is a stated priority.
• Excellence: The company describes its goal as being a trusted partner to pharmaceutical organizations, not solely a software vendor, with a focus on elevating scientific dialogue and turning evidence into actionable narratives.

Polarix.io is available via a demo request and targets organizations looking to standardize, scale, and improve the reach of their scientific communications across internal and external audiences.